The aim of Work package 1 was to propose a fractional pharmacokinetic model suitable for the analysis of methotrexate (MTX) distribution within the human body during a chemotherapy session. This informed the proposal of criterion for optimising chemotherapy administration, providing isoperimetric and minimal toxicity constraints and the development of numerical procedures suitable for the optimal control problem posed. The key novelty of this project was solving the current problem of uncontrolled dosing regimens with an innovative fractional pharmacokinetic model capable of addressing theoretical and practical aspects of treatments simultaneously. Anomalous between-patient rates of perfusion of a specific drug are accounted for in a calculated, optimally individualised drug administration protocol, which is then implemented by the manufactured microfluidic electronic device.
The objective of Work package 2 was to develop and test innovative microfluidic devices for optimal drug delivery using a cost effective rapid prototyping 3D printing process. The MEDLEM team developed microfluidic chips using a 3D rapid prototyping process, but we also created chips in PDMS technology and using a xurographic technique as well as with hybrid processes combining these methods. The MEDLEM project provides modern, flexible microfluidic chips capable of optimally delivering drugs using personalized and tailored nano and micro technologies.
Among the wide variety of drugs that could be chosen to treat cancer, the MEDLEM project addressed the pharmacokinetics of methotrexate (MTX). Being the most commonly used antimetabolite in cancer therapy, MTX was chosen for its wide dose range and because it has an antidote (leucovorine) in clinical use. A special feature of this study was the recognition and monitoring of potential problems at the commencement of MTX administration. This will enable accurate, precise and concise medical measurements to improve therapy and reduce side effects, transforming patients’ experiences and long-term prognosis.
Impacts of the project: The MEDLEM project has a significant impact on solving societal challenge such as leukaemia treatment on a creative way through fabrication of cost-effective microfluidic chips for optimal MTX dosage. According to the Innovate Union, strengthening of scientific cooperation between Europe and third countries (in MEDLEM case, Australia and Thailand) will contribute to global approaches and solutions to societal challenges and to the establishment of a long-term partnership. MEDLEM team developed 10 different microfluidic chips capable of optimally delivering drugs using personalized and tailored nano and micro technologies as well as improving leukaemia treatment, providing significant benefit for European and worldwide society.
